Subscribe to Journal
Get full journal access for 1 year
only $89.17 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.
Jackson G, Davies FE, Pawlyn C, Cairns DA, Striha A, Collettet C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57–73.
Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegmanet S, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2017;32:383–90.
Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119:940–8.
Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulosm S, Kang Y, et al. Outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transpl. 2017;23:262–8.
Jackson G, Davies FE, Pawlyn C, Cairns D, Striha A, Hockaday A, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130(Suppl 1):436.
Conflict of interest
KM has received honoraria from Janssen, Celgene, Takeda, and Amgen. PT has received honoraria from Janssen, Celgene, Bristol-Myer Squibb, and Amgen. LP has received honoraria from Janssen, Celgene, and Takeda. MC has received honoraria and served on the advisory board for Janssen, Celgene, Bristol-Myer Squibb, Takeda, Amgen, and Novartis. EZ has received honoraria from and served on the advisory board for Janssen, Celgene, Bristol-Myer Squibb, Takeda, and Amgen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the paper apart from those disclosed.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mancuso, K., Tacchetti, P., Pantani, L. et al. Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-0844-2